TELA Bio, Inc. (TELA)
TELA Bio, Inc. operates in the Medical - Devices industry of the Healthcare sector, headquartered in Malvern, PA, US. The stock last traded at $0.74, down 6.16% on the session, giving a market capitalisation of $33.2M. On trailing twelve-month figures it carries a trailing P/E of -0.96, a net margin of -51.5%. Its beta of 1.36 implies it has historically moved more than the broad market.
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
TELA Bio, Inc. is most often compared with the following Healthcare names: